| __timestamp | CymaBay Therapeutics, Inc. | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 660772000 |
| Thursday, January 1, 2015 | 8871000 | 736435000 |
| Friday, January 1, 2016 | 9645000 | 775266000 |
| Sunday, January 1, 2017 | 12387000 | 860348000 |
| Monday, January 1, 2018 | 14381000 | 814775000 |
| Tuesday, January 1, 2019 | 19238000 | 942821000 |
| Wednesday, January 1, 2020 | 17425000 | 985616000 |
| Friday, January 1, 2021 | 23040000 | 1061508000 |
| Saturday, January 1, 2022 | 25116000 | 1190423000 |
| Sunday, January 1, 2023 | 51953000 | 1254234000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Grifols, S.A. and CymaBay Therapeutics, Inc. from 2014 to 2023. Over this period, Grifols consistently outspent CymaBay, with its SG&A expenses peaking at approximately 1.25 billion in 2023, marking a 90% increase from 2014. In contrast, CymaBay's SG&A expenses saw a more dramatic rise, surging over 500% to reach around 52 million in 2023. This stark difference highlights Grifols' established market presence and CymaBay's aggressive growth strategy. As the pharmaceutical landscape continues to shift, these spending patterns offer valuable insights into each company's operational focus and market positioning.
AstraZeneca PLC and Grifols, S.A.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Sanofi vs CymaBay Therapeutics, Inc.
BeiGene, Ltd. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Grifols, S.A.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Xenon Pharmaceuticals Inc. Trends and Insights
CymaBay Therapeutics, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Evotec SE